CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, ShermanSI, TuttleRM. American Thyroid Association Guidelines Taskforce. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109–142.
2.
PaciniF, SchlumbergerM, DralleH, EliseiR, SmitJW, WiersingaW. European Thyroid Cancer Taskforce. 2006. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154:787–803.
3.
SosaJA, UdelsmanR. 2006. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol, 94:701–707.
4.
ChisholmEJ, KulinskayaE, TolleyNS. 2009. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope, 119:1135–1139.
5.
RotsteinL. 2009. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol, 99:186–188.
6.
CartySE, CooperDS, DohertyGM, DuhQY, KloosRT, MandelSJ, RandolphGW, StackBC, StewardDL, TerrisDJ, ThompsonGB, TufanoRP, TuttleRM, UdelsmanR. 2009. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid, 19:1153–1158.
7.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
8.
PerrinoM, VannucchiG, VicentiniL, CantoniG, DazziD, ColomboC, RodariM, ChitiA, Beck-PeccozP, FugazzolaL. 2009. Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or = 2 cm. Endocr Relat Cancer, 16:201–210.
9.
MooTA, McGillJ, AllendorfJ, LeeJ, FaheyT3rd, ZarnegarR. 2010. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg, 34:1187–1191.
10.
ZetouneT, KeutgenX, BuitragoD, AldailamiH, ShaoH, MazumdarM, FaheyTJ3rd, ZarnegarR. 2010. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol, 17:3287–3293.
11.
MonchikJM, SimonCJ, CaragacianuDL, ThomayAA, TsaiV, CohenJ, MazzagliaPJ. 2009. Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid?Surgery, 146:1182–1187.
12.
HughesDT, WhiteML, MillerBS, GaugerPG, BurneyRE, DohertyGM. 2010. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery, 148:1100–1106.
13.
CarlingT, CartySE, CiarleglioMM, CooperDS, DohertyG, KimLT, KloosRT, MazzaferriE, PeduzziPN, RomanS, SippelRS, SosaJA, StackBC, StewardD, TufanoRP, TuttleRM, UdelsmanR. 2011. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid, 22:237–244.
14.
National Institutes of Health. Prophylactic central lymph node dissection in papillary thyroid microcarcinoma. http://clinicaltrials.gov/ct2/show/NCT00795782?term=Prophylactic+central+lymph+node+dissection+in+papillary+thyroid+microcarcinoma&rank=1. 2012 January 29.
15.
MorenoMA, Edeikin-MonroeBS, SiegelER, ShermanSI, ClaymanGL. 2012. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid, 22:347–355.
16.
BonnetS, HartlD, LeboulleuxS, BaudinE, LumbrosoJD, Al GhuzlanA, ChamiL, SchlumbergerM, TravagliJP. 2009. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab, 94:1162–1167.
17.
RandolphGW, DuhQ-Y, HellerKS, LiVolsiVA, MandelSJ, StewardDL, TufanoRP, TuttleRM. The prognostic significance of nodal metastases from papillary thyroid cancer can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension: report of the ATA Surgical Affairs Committee. Thyroid(submitted for publication).
18.
TeixeiraG, TeixeiraT, GubertF, ChikotaH, TufanoRP. 2011. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery, 150:1161–1167.
19.
TufanoRP, TeixeiraGV, BishopJ, CarsonKA, XingM. 2012. BRAF mutation in papillary thyroid cancer, its value in tailoring initial treatment: a systematic review, meta-analysis. Medicine(in press).
20.
TufanoRP, BishopJ, WuG. The association between the BRAF mutation status and the clinicopathologic characteristics and outcomes of patients with recurrent/persistent papillary thyroid cancer in the central neck that have undergone re-operative central compartment dissection. Laryngoscope(submitted for publication).
21.
O'NeillCJ, BullockM, ChouA, SidhuSB, DelbridgeLW, RobinsonBG, GillAJ, LearoydDL, Clifton-BlighR, SywakMS. 2010. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery, 148:1139–1145.
